The place of metformin in the treatment of carbohydrate metabolism disorders and insulin resistance during, before and after pregnancy: resolution of the expert council

Due to its effect on insulin resistance, ease of administration and favorable safety profile, metformin has been included in the recommendations of foreign medical communities for the management of pregnant women with hyperglycemia since 2008. However, in Russia, the use of any oral hypoglycemic agents during pregnancy is still contraindicated. However, recent studies demonstrate the safety and positive effects of metformin on pregnancy in patients with pregestational diabetes mellitus, polycystic ovary syndrome and gestational diabetes mellitus. In 2023, the Federal Service for Surveillance in Healthcare of the Ministry of Health of Russia updated the instructions for the medical use of Glucophage® and Glucophage®Long: pregnancy was excluded from the “Contraindications” section and moved to the “With caution” section. This resolution is intended to evaluate studies of the effectiveness and safety of metformin, as well as to study the experience of foreign colleagues and Russian legal aspects of prescribing metformin in the stages of preparation for pregnancy, during it and in the post-gravid period.

1. Gestational diabetes. International Diabetes Federation. [Accessed: 2023 Nov 27]

2. McIntyre HD, Fuglsang J, Kampmann U, Knorr S, Ovesen P. Hyperglycemia in Pregnancy and Women’s Health in the 21st Century. Int J Environ Res Public Health. 2022;19(24):16827. doi: https://doi.org/10.3390/ijerph192416827

3. Office of the Federal State Statistics Service for the Sverdlovsk Region and Kurgan Region - Population [Internet](In Russ.)

4. Malaza N, Masete M, Adam S, et al. A Systematic Review to Compare Adverse Pregnancy Outcomes in Women with Pregestational Diabetes and Gestational Diabetes. Int J Environ Res Public Health. 2022;19(17):10846. doi: https://doi.org/10.3390/ijerph191710846

5. Freinkel N. Banting Lecture 1980: of Pregnancy and Progeny. Diabetes. 1980;29(12):1023–35. doi: https://doi.org/10.2337/diab.29.12.1023

6. Hart BN, Shubrook JH, Mason T. Pregestational Diabetes and Family Planning. Clin Diabetes. 2021;39(3):323–8. doi: https://doi.org/10.2337/cd20-0062

7. Hughes RCE, Moore MP, Gullam JE, et al. An early pregnancy HbA1c ≥5.9% (41 mmol/mol) is optimal for detecting diabetes and identifies women at increased risk of adverse pregnancy outcomes. Diabetes Care. 2014;37(11):2953–9. doi: https://doi.org/10.2337/dc14-1312

8. Mañé L, Flores-Le Roux JA, Benaiges D, et al. Role of First-Trimester HbA1c as a Predictor of Adverse Obstetric Outcomes in a Multiethnic Cohort. J Clin Endocrinol Metab. 2017;102(2):390–7. doi: https://doi.org/10.1210/jc.2016-2581

9. Schiller T, Barak O, Winter Shafran Y, et al. Prediabetes in pregnancy – follow-up, treatment, and outcomes compared to overt pregestational diabetes. The Journal of Maternal-Fetal & Neonatal Medicine. 2023;36(1):2191153. doi: https://doi.org/10.1080/14767058.2023.2191153

10. Russian Association of Endocrinologists. Clinical guidelines “Type 2 diabetes mellitus in adults.” 2022 (In Russ.)

11. Allen AJ, Snowden JM, Lau B, et al. Type-2 diabetes mellitus: does prenatal care affect outcomes? J Matern Fetal Neonatal Med. 2018;31(1):93–7. doi: https://doi.org/10.1080/14767058.2016.1276558

12. Yamamoto JM, Hughes DJF, Evans ML, et al. Communitybased pre-pregnancy care programme improves pregnancy preparation in women with pregestational diabetes. Diabetologia. 2018;61(7):1528–37. doi: https://doi.org/10.1007/s00125-018-4613-3

13. Sharpe A, Morley LC, Tang T, et al. Metformin for ovulation induction (excluding gonadotrophins) in women with polycystic ovary syndrome. Cochrane Database Syst Rev. 2019;2019(12):CD013505. doi: https://doi.org/10.1002/14651858.CD013505

14. Teede HJ, Tay CT, Laven JJE, et al. Recommendations from the 2023 international evidence-based guideline for the assessment and management of polycystic ovary syndrome. Eur J Endocrinol. 2023;189(2):G43–64. doi: https://doi.org/10.1093/ejendo/lvad096

15. Sonagra AD, Biradar SM, K. D, et al. Normal Pregnancy- A State of Insulin Resistance. J Clin Diagn Res. 2014;8(11):CC01–3. doi: https://doi.org/10.7860/JCDR/2014/10068.5081

16. Kampmann U, Knorr S, Fuglsang J, et al. Determinants of Maternal Insulin Resistance during Pregnancy: An Updated Overview. J Diabetes Res. 2019;2019:5320156. doi: https://doi.org/10.1155/2019/5320156

17. Yeh T, Yeung M, Mendelsohn Curanaj FA. Inpatient Glycemic Management of the Pregnant Patient. Curr Diab Rep. 2018;18(10):73. doi: https://doi.org/10.1007/s11892-018-1045-x

18. Lawal SK, Adeniji AA, Sulaiman SO, et al. Comparative effects of glibenclamide, metformin and insulin on fetal pancreatic histology and maternal blood glucose in pregnant streptozotocininduced diabetic rats. Afr Health Sci. 2019;19(3):2491–504. doi: https://doi.org/10.4314/ahs.v19i3.25

19. Nguyen L, Chan S-Y, Teo AKK. Metformin from mother to unborn child – Are there unwarranted effects? EBioMedicine. 2018;35:394–404. doi: https://doi.org/10.1016/j.ebiom.2018.08.047

20. Pollex EK, Feig DS, Lubetsky A, et al. Insulin Glargine Safety in Pregnancy. Diabetes Care. 2010;33(1):29–33. doi: https://doi.org/10.2337/dc09-1045

21. Menon RK, Cohen RM, Sperling MA, et al. Transplacental passage of insulin in pregnant women with insulindependent diabetes mellitus. Its role in fetal macrosomia. N Engl J Med. 1990;323(5):309–15. doi: https://doi.org/10.1056/NEJM199008023230505

22. Vanky E, Stridsklev S, Heimstad R, et al. Metformin versus placebo from first trimester to delivery in polycystic ovary syndrome: a randomized, controlled multicenter study. J Clin Endocrinol Metab. 2010;95(12):E448-455. doi: https://doi.org/10.1210/jc.2010-0853

23. Feig DS, Donovan LE, Zinman B, et al. Metformin in women with type 2 diabetes in pregnancy (MiTy): a multicentre, international, randomised, placebo-controlled trial. The Lancet Diabetes & Endocrinology. 2020;8(10):834–44. doi: https://doi.org/10.1016/S2213-8587(20)30310-7

24. Feig DS, Sanchez JJ, Murphy KE, et al. Outcomes in children of women with type 2 diabetes exposed to metformin versus placebo during pregnancy (MiTy Kids): a 24-month follow-up of the MiTy randomised controlled trial. Lancet Diabetes Endocrinol. 2023;11(3):191–202. doi: https://doi.org/10.1016/S2213-8587(23)00004-9

25. Rowan JA, Hague WM, Gao W, et al. Metformin versus Insulin for the Treatment of Gestational Diabetes. New England Journal of Medicine. 2008;358(19):2003–15. doi: https://doi.org/10.1056/NEJMoa0707193

26. Rowan JA, Rush EC, Plank LD, et al. Metformin in gestational diabetes: the offspring follow-up (MiG TOFU): body composition and metabolic outcomes at 7–9 years of age. BMJ Open Diabetes Res Care. 2018;6(1):e000456. doi: https://doi.org/10.1136/bmjdrc-2017-000456

27. Clausen TD, Mathiesen E, Ekbom P, et al. Poor pregnancy outcome in women with type 2 diabetes. Diabetes Care. 2005;28(2):323–8. doi: https://doi.org/10.2337/diacare.28.2.323

28. Verheijen ECJ, Critchley JA, Whitelaw DC, et al. Outcomes of pregnancies in women with pre-existing type 1 or type 2 diabetes, in an ethnically mixed population. BJOG. 2005;112(11):1500–3. doi: https://doi.org/10.1111/j.1471-0528.2005.00747.x

29. Asbjörnsdóttir B, Rasmussen SS, Kelstrup L, et al. Impact of restricted maternal weight gain on fetal growth and perinatal morbidity in obese women with type 2 diabetes. Diabetes Care. 2013;36(5):1102–6. doi: https://doi.org/10.2337/dc12-1232

30. Sato T, Sugiyama T, Kurakata M, et al. Pregnancy outcomes in women with type 1 and type 2 diabetes mellitus in a retrospective multi-institutional study in Japan. Endocr J. 2014;61(8):759–64. doi: https://doi.org/10.1507/endocrj.ej14-0140

31. Gur’eva VM, et al. Pregnancy complications and perinatal outcomes in women with type 2 diabetes mellitus. Russian Bulletin of Obstetrician-Gynecologist. 2013;13(1):37-41. (In Russ.).

32. Hyperglycemia and Adverse Pregnancy Outcomes. New England Journal of Medicine. 2008;358(19):1991–2002. doi: https://doi.org/10.1056/NEJMoa0707943

33. Dedov II, Shestakova MV, Mayorov AYu, et al. Standards of specialized diabetes care. 11th edition. Moscow, 2023 (In Russ.)] doi: https://doi.org/10.14341/DM13042

34. Russian Association of Endocrinologists, Russian Society of Obstetricians and Gynecologists. Russian national consensus «Gestational diabetes mellitus: diagnosis, treatment, postpartum care». 2013 [cited 2023 Nov 27]; Available from: https://rae-org.ru/system/files/documents/pdf/rek_gest_dm_2013.pdf (in Russ.)

35. Balsells M, García-Patterson A, Solà I, et al. Glibenclamide, metformin, and insulin for the treatment of gestational diabetes: a systematic review and meta-analysis. BMJ. 2015;350:h102. doi: https://doi.org/10.1136/bmj.h102

36. Hanem LGE, Salvesen Ø, Juliusson PB, et al. Intrauterine metformin exposure and offspring cardiometabolic risk factors (PedMet study): a 5-10 year follow-up of the PregMet randomised controlled trial. Lancet Child Adolesc Health. 2019;3(3):166–74. doi: https://doi.org/10.1016/S2352-4642(18)30385-7

37. Tartarin P, Moison D, Guibert E, et al. Metformin exposure affects human and mouse fetal testicular cells. Human Reproduction. 2012;27(11):3304–14. doi: https://doi.org/10.1093/humrep/des264

38. American Diabetes Association Professional Practice Committee. 15. Management of Diabetes in Pregnancy: Standards of Care in Diabetes—2024. Diabetes Care. 2023;47(Supplement_1):S282–94. doi: https://doi.org/10.2337/dc24-S015

39. NICE. Diabetes in pregnancy: management from preconception to the postnatal period [Internet]. NICE; 2020 [Accessed: 2023 Nov 27]

40. SMFM Statement: Pharmacological treatment of gestational diabetes. American Journal of Obstetrics & Gynecology. 2018;218(5):B2–4. doi: https://doi.org/10.1016/j.ajog.2018.01.041

41. American College of Obstetricians and Gynecologists’ Committee on Practice Bulletins—Obstetrics. ACOG Practice Bulletin No. 201: Pregestational Diabetes Mellitus. Obstet Gynecol. 2018;132(6):e228–48. doi: https://doi.org/10.1097/AOG.0000000000002960

42. ACOG Practice Bulletin No. 190: Gestational Diabetes Mellitus. Obstetrics & Gynecology. 2018;131(2):e49. doi: https://doi.org/10.1097/AOG.0000000000002501

43. Diabetes Canada Clinical Practice Guidelines Expert Committee. Diabetes Canada 2018 clinical practice guidelines for the prevention and management of diabetes in Canada. Can J Diabetes. 2018;42(Suppl 1):S1–325

44. Blumer I, Hadar E, Hadden DR, et al. Diabetes and Pregnancy: An Endocrine Society Clinical Practice Guideline. The Journal of Clinical Endocrinology & Metabolism. 2013;98(11):4227–49. doi: https://doi.org/10.1210/jc.2013-2465

45. Queensland Clinical Guidelines. Maternity and Neonatal Clinical Guideline. Gestational diabetes mellitus (GDM). 2021; Available at: https://www.health.qld.gov.au/__data/assets/pdf_file/0022/950503/g-gdm.pdf

46. Rudland VL, Price SAL, Hughes R, et al. ADIPS 2020 guideline for pre-existing diabetes and pregnancy. Australian and New Zealand Journal of Obstetrics and Gynaecology. 2020;60(6):E18–52. doi: https://doi.org/10.1111/ajo.13265

47. Daly B, Toulis KA, Thomas N, et al. Increased risk of ischemic heart disease, hypertension, and type 2 diabetes in women with previous gestational diabetes mellitus, a target group in general practice for preventive interventions: A population-based cohort study. PLoS Med. 2018;15(1):e1002488. doi: https://doi.org/10.1371/journal.pmed.1002488

48. Li Z, Cheng Y, Wang D, et al. Incidence Rate of Type 2 Diabetes Mellitus after Gestational Diabetes Mellitus: A Systematic Review and Meta-Analysis of 170,139 Women. J Diabetes Res. 2020;2020:3076463. doi: https://doi.org/10.1155/2020/3076463

49. Elbeltagi R, Al-Beltagi M, Saeed NK, et al. Cardiometabolic effects of breastfeeding on infants of diabetic mothers. World J Diabetes. 2023;14(5):617–31. doi: https://doi.org/10.4239/wjd.v14.i5.617

50. Gunderson EP. Breast-Feeding and Diabetes: Long-Term Impact on Mothers and Their Infants. Curr Diab Rep. 2008;8(4):279–86

51. Wu P, Park K, Gulati M. The Fourth Trimester: Pregnancy as a Predictor of Cardiovascular Disease. Eur Cardiol. 2021;16:e31. doi: https://doi.org/10.15420/ecr.2021.18

52. “Glucophage” Drug Label №P N014600/01 (in Russ.)

53. Glucophage® Long 500 mg Drug Label №LSR-002098/10; Glucophage® Long 750 mg Drug Label №LP-000509; Glucophage® Long 1000 mg Drug Label №LP-002396 (in Russ.)